Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So 2024 can be another incredible year |
| And we have a huge opportunity there, and we're making incredible progress with health systems, payers, the brand awareness of Cologuard |
| It was at 1.2 million new patients becoming eligible for the last couple of years, and also, our success rate at getting those people back to Cologuard continues to grow |
| So 60% feel good about that, and there's a long runway ahead here |
| We're set to gain momentum as we bring these new tests to physicians and patients at regular intervals over the next few years |
| Highlights in 2023 include testing a record 4.1 million patients for cancer and rare diseases, growing core revenue by 24% to $2.5 billion, improving adjusted EBITDA $362 million year-over-year, turning free cash flow positive, submitting next-generation Cologuard for FDA approval, launching Oncotype DX in Japan on a reimbursed basis, accelerating our molecular residual disease or MRD program, launching OncoExTra, our solid tumor therapy selection test, and adding OncoLiquid, our liquid therapy selection test and advancing our multi-cancer early detection |
| That's very good |
| 2023 was another record-breaking year for Exact Sciences and our fourth quarter results set the tone for an impactful year ahead |
| And it ends up leading to significant growth and profitability |
| We continue to see broad-based momentum in Cologuard adoption by healthcare providers with an all-time high 172,000 ordering Cologuard during the quarter |
| This expanded base of [ordering providers] (ph) supports our long-term growth outlook |
| So even where we're at today is a good outcome, we think we can do even better though |
| The team has done a nice job executing there |
| Net loss was $50 million, and adjusted EBITDA was $50 million, an improvement of $45 million driven by better-than-expected revenue and continued operating expense discipline |
| So hugely proud of the team here in San Diego and also equally proud of the team in our Phoenix lab, who is working through the validation of that test at breakneck speed |
| I've recently just participated in our global sales meeting and I'm just telling you our -- to ahead, everybody feels that we have an incredible opportunity to continue this growth to fulfill our mission |
| In Precision Oncology, we expect steady Oncotype DX growth in the US and strong double-digit growth internationally this year |
| The team did a great job implementing automation within our state-of-the-art labs, which will drive gross margin expansion this year and beyond |
| It's an exciting time with Precision Oncology continued growth and node positive internationally and then just a number of new product launches over the next two years |
| And that's why we feel very confident that for years and years to come, colonoscopy and Cologuard will be the two leading tests and you're seeing that today as Cologuard takes share away from the FIT test, colonoscopy volume, screening colonoscopy volumes haven't changed in a meaningful way in a decade |
| The momentum is something that is generating enthusiasm across internally and also our important customer and patient base that we take care of, there's still 60 million people out there still this year, like there was last year that are not up to date with screening |
| Brand awareness and loyalty are fueling Cologuard adoption and helping reach 60 million Americans who are not up to date with colon cancer screening |
| Marketing, as an example, we're being very smart at the way we're taking advantage of key growth levers like rescreens, our 45 to 49 segment, which is fantastic opportunities for growth |
| And that provides a cost structure that we believe will be best-in-class and provide real value to the health system and to those patients that get tested |
| We're building on this momentum by helping health systems achieve positive clinical and financial outcomes, designing innovative ways to get more patients rescreened and partnering with federally qualified health centers and healthcare providers that serve diverse communities |
| We've built a strong foundation |
| But the team is focused and we're really excited about the path ahead |
| Everett's done a really nice job of leading this team, but we see such strong return on investment there that we are going to raise some investment there |
| And two, it allows us to track more mutations in a patient's blood at a very, very attractive cost point |
| Further embedding Cologuard as standard-of-care, increasing Oncotype DX adoption internationally, advancing key pipeline programs, deepening relationships with health systems, and delivering experiences that patients and providers love |
| Statement |
|---|
| It's related to physician office visits around Christmas and New Year’s are slower which hits -- hurts Q1 revenue |
| Think of our screening business down sequentially |
| We expect first quarter screening revenue to be down sequentially because of typical seasonal trends |
| [You see] (ph) blood falls off by like 25% because of the lack of sensitivity of refining precancerous polyps |
| Maybe first on the screening guide, you've been clear in the past to expect 1Q to be down sequentially |
| Starting in the first quarter, we're assuming a $20 million headwind or 3 points of revenue growth for Precision Oncology as various agreements related to whole exome sequencing and prostate cancer testing are transitioned in-house by those ordering labs |
| So that's over the year, expected to be a $20 million headwind, probably hurts Q1 a bit more than Q4, but that's the annual impact |
| With respect to OncoDetect, we'll be asking a patient to do a test every three months, which is very difficult and challenging, particularly in the out years, when a patient is tested negative for three, four years consecutively |
| Our challenge is to make this -- to hit the easy button |
| And this is the challenge |
| And what you'll see is these blood tests generate a lot of false positives |
| So you're in this difficult place to get onto this efficient frontier as it's called |
| Sales and marketing after the last two years where that had come down in absolute terms |
| The success rate is a bit below what you said today |
| And these are difficult challenges |
| That's a little light |
| This is the challenge, to getting an A or B rated test |
| So we couldn't be more excited |
| We're still waiting on progress in BC around the Medicare benefit |
| And it's very difficult to get into the guidelines with the performance characteristics of what we see today in this category of tests |
Please consider a small donation if you think this website provides you with relevant information